Skip to main content
. Author manuscript; available in PMC: 2021 Sep 13.
Published in final edited form as: J Thorac Oncol. 2020 Jan 28;15(5):843–859. doi: 10.1016/j.jtho.2020.01.012

Figure 2. BAP1 DUB activity does not correlate with sensitivity to PARPIs in patient-derived mesothelioma cell lines; however, all the cell lines sensitive to PARPIs are SFN11-positive.

Figure 2.

(A) Summary of BAP1 and SFN11 protein expression in ten patient-derived mesothelioma cell lines and their corresponding IC50 for olaparib and talazoparib. (B) Graphical scatter plot based on IC50 of olaparib vs talazoparib shows a clear separation of sensitive (red open oval) and resistant (blue open oval) cell line clusters. One (NCI-Meso17) out of three cell lines having catalytically active BAP1 (red dots) are sensitive while other two (NCI-Meso18 and NCI-Meso19) are resistant. Likewise, NCI-Meso21 (blue dot within red oval) being sensitive to PARPIs does not contain catalytically active BAP1. This data suggests that patient-derived mesothelioma cellular sensitivity to PARPIs does not depend on the activity of BAP1. (C) The sensitivity plot shows SLFN11 expression level. All the SLFN11-negative cells (blue dots) are clustered within resistant group while the SLFN11-positive cells (red dots) are present in both the clusters. Number on each dotted plot represent the cell lines having “NCI-Meso” as prefix.